IQV Price Prediction Next Week
Analysis and Insights
Technical Analysis:
IQV's stock price is currently trading at $192 as of March 7, 2025. The technical indicators suggest a mixed outlook:
- RSI: The RSI values (58.48 for RSI_6, 48.43 for RSI_12, and 47.49 for RSI_14) indicate that the stock is not in overbought territory, but it is approaching neutral levels.
- Stochastic Oscillator: The StochK (41.24) and StochD (28.97) suggest bearish momentum, but the stock is not yet oversold.
- MACD: The MACD (-3.72) and MACD Histogram (-0.29) indicate bearish momentum, but the small negative value of the histogram suggests weakening bearish strength.
- Moving Averages: The SMA_5 ($186.27), SMA_10 ($188.33), and SMA_20 ($193.07) are all below the current price, indicating a potential downtrend.
- Fibonacci Levels: The pivot point is at $187.77, with resistance levels at $194.04 and $197.91, and support levels at $181.50 and $177.63.
News and Event Impact:
- Event Announcement: IQVIA Holdings Inc. presented at the TD Cowen Annual Health Care Conference on March 4, 2025, which could positively impact investor sentiment.
- Analyst Update: Citi analyst Patrick Donnelly lowered the price target from $225 to $210, maintaining a Neutral rating, citing light investor appetite in the sector.
- Insider Activity: A director at IQV bought 1,275 shares on December 3, 2024, which could signal confidence in the company's future prospects.
Price Prediction and Recommendation:
Based on the technical indicators and news sentiment, IQV is expected to trade in a range between $187.77 and $194.04 next week. The stock is likely to face resistance at $194.04 and support at $187.77. Given the current price of $192 and the mixed technical indicators, the stock is expected to reach $194 by the end of the next trading week.
Recommendation: Buy IQV at the current price of $192 with a target price of $194.
IQV Similar Chart Price Prediction
The price of IQV is predicted to go up -17.82%, based on the high correlation periods with RYI. The similarity of these two price pattern on the periods is 96.98%.
IQV
RYI
Down: -17.82%Similarity: 96.98%
IQV Revenue Forecast
IQV EPS Forecast
IQV FAQs
What is IQV revenue forecast for next quarter？
What is IQV eps forecast for next quarter？
IQV VS S&P500
IQVIA's leading position in outsourced clinical trials allows it to create sticky client relationships, further honing clinical and regulatory expertise.
The merger with IMS Health provided access to an unparalleled database of patient data, which should strengthen its clinical trial offerings.
The ongoing shift to outsourced R&D should provide the CRO industry with steady growth regardless of trends in global research and development spending.
IQV Analyst's Forecast
Patrick Donnelly
Citigroup
Hold
2025-03-04
Price Target
$225 → $210
Upside
+14.4%
Citi analyst Patrick Donnelly lowered the firm's price target on Iqvia to $210 from $225 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Coming away from earnings, investor appetite for the sector "remains very light," primarily due to ongoing U.S. government pressure, the analyst tells investors in a research note. However, Citi sees pockets of the market to be constructive on, such as bioprocessing, where it believes a recovery is underway. Danaher (DHR) is the firm's top pick.
Eric Coldwell
Baird
Hold
2025-01-21
Price Target
$212 → $210
Upside
+2.1%
Jeff Garro
Stephens & Co.
Buy
2024-12-20
Price Target
$250
Upside
+26.73%
